{
    "clinical_study": {
        "@rank": "15220", 
        "brief_summary": {
            "textblock": "To identify the causative mutations in previously untreated patients with hemophilia A\n      enrolled in the ReFacto\u00ae clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using\n      two established hemophilia mutation testing laboratories (one in Europe and one in North\n      America)."
        }, 
        "brief_title": "Study Evaluating ReFacto in Hemophilia A", 
        "completion_date": {
            "#text": "May 2001", 
            "@type": "Actual"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been\n             treated with ReFacto\u00ae during this study are eligible for participation.\n\n          -  The patient (or legal guardian) must be willing to give written informed consent\n             before any study-related procedures are performed.\n\n          -  A blood sample will be collected from each patient for the purpose of this study and\n             will be analyzed at one or both of the designated central laboratories.\n\n        Exclusion Criteria:\n\n          -  Any condition which, in the investigator's opinion, places the patient at undue risk."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "103", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 5, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038909", 
            "org_study_id": "3082A1-302"
        }, 
        "intervention": {
            "intervention_name": "BDDrFVII", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 7, 2013", 
        "official_title": "Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto\u00ae Study", 
        "overall_official": {
            "affiliation": "Wyeth is now a wholly owned subsidiary of Pfizer", 
            "last_name": "Medical Monitor, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038909"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 1994", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }, 
    "geocoordinates": {}
}